Lv28
180 积分 2023-12-27 加入
Atrasentan in Patients with IgA Nephropathy
2天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2天前
已完结
Atrasentan in Patients with IgA Nephropathy
2天前
已完结
Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC
3天前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
4天前
已完结
Sparsentan in Patients with IgA Nephropathy (PROTECT): A Randomised Double-Blind Active-Controlled Clinical Trial
5天前
已关闭
Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results
6天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
11天前
已完结
Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy
1个月前
已完结
Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery
1个月前
已完结
皖公网安备34019202002308
